This suggests that IDHmut by itself acts in a relatively indolent manner, and that most cases coming to clinical attention do so because they acquire additional TP53 and ATRX alterations (or TERT promoter mutations and 1p/19q codeletion), thereby accelerating tumor proliferation and evolution. This evidence concerns the gene TP53 and neoplasm.